News

10/23/2021

CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility

CEL-SCI Corporation announced it has completed the expansion of its existing dedicated Multikine* (Leukocyte Interleukin, Injection) cGMP manufacturing facility. The expansion was undertaken in anticipation of filing a Biologics License Application (BLA) which, if approved, will allow Multikine produced in the facility to be commercially distributed. The construction, which began in 2020, expanded the facility and

10/21/2021

RIVANNA announces award from U.S. government to develop Accuro Platform for rapid triage of blast-related injuries

RIVANNA®, developers of imaging-based medical solutions, announced that they have received a contract from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the design and development of a computer-aided 3D

10/20/2021

ATCC Hires New Chief Commercial Officer

ATCC, the world’s premier biological materials management and standards organization, today announced it has hired Greg Ballish as its new Chief Commercial Officer. In his role, Ballish will head ATCC’s sales and marketing operations and partner with Ruth Cheng, Ph.D., Chief Innovation and Strategy Officer and Vice President of Corporate Development of ATCC, to oversee

10/20/2021

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

Contraline, Inc., a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective male contraception, has closed $10.7 million in its Series A financing. The financing round was led by MBX Capital, a venture capital firm that invests in early-stage healthcare and life sciences companies. Additional investors in Contraline include:

10/19/2021

AgroSpheres Awarded Competitive SBIR Phase II Grant from the National Science Foundation to Combat Fall Armyworm

AgroSpheres, Inc. has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant for $999,653 to progress its R&D collaboration with the University of Tennessee on an RNAi biological insecticide targeting fall armyworm (FAW). Larvae of FAW are one of the most economically devastating insect pests in its native region

10/18/2021

What Virginia’s next governor should do to protect innovation, help prevent the next pandemic

The ongoing struggle with the COVID-19 pandemic and the emergence of its delta variant have highlighted the critical role of Virginia’s life sciences companies in combating significant public health threats. In near-record time, biotechnology companies developed effective COVID treatments, vaccines and tests, all while being a major economic and jobs driver in the commonwealth. However,